PRESS RELEASES

Date Title and Summary View
Mar 1, 2016
Summary ToggleZafgen to Present at the Cowen & Company 36th Annual Health Care Conference
BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that Thomas Hughes, Chief Executive Officer of Zafgen,
Summary ToggleZafgen to Present at the Cowen & Company 36th Annual Health Care Conference
Feb 29, 2016
Summary ToggleZafgen Joins NORD in Raising Awareness of Rare Disease Day Summary ToggleZafgen Joins NORD in Raising Awareness of Rare Disease Day
Feb 18, 2016
Summary ToggleZafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint
- Beloranib demonstrates statistically and clinically significant improvements in body weight and glycemic control over six months of randomized treatment — -Conference call scheduled for 8:30 AM Eastern Time- BOSTON, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Zafgen (Nasdaq:ZFGN), a biopharmaceutical
Summary ToggleZafgen's Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint
Feb 16, 2016
Summary ToggleZafgen to Participate in Upcoming Investor Conferences
BOSTON, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will participate in two upcoming investor
Summary ToggleZafgen to Participate in Upcoming Investor Conferences
Feb 2, 2016
Summary ToggleZafgen to Present at Upcoming Investor Conferences
BOSTON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will present at two upcoming investor
Summary ToggleZafgen to Present at Upcoming Investor Conferences
Jan 20, 2016
Summary ToggleZafgen's Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints
- bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improve hyperphagia-related behaviors in PWS patients- -Statistically significant at both 2.4 mg and 1.8 mg dose levels- -Company plans to discuss results and path forward for beloranib with the FDA- -Conference
Summary ToggleZafgen's Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints
Dec 2, 2015
Summary ToggleZafgen Announces Beloranib IND Placed on Complete Clinical Hold
BOSTON, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today received verbal notice from the U.S.
Summary ToggleZafgen Announces Beloranib IND Placed on Complete Clinical Hold
Dec 2, 2015
Summary ToggleZafgen Provides Clinical Update on Beloranib
BOSTON, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today provided an update on the open label extension (OLE) portion of the
Summary ToggleZafgen Provides Clinical Update on Beloranib
Nov 10, 2015
Summary ToggleZafgen Announces Third Quarter 2015 Financial Results
Company to Host Conference Call at 4:30 PM Eastern Time to Review Progress with Beloranib Program Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $204 Million; Increases Year-End Cash Guidance to Greater than $180 Million BOSTON, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc.
Summary ToggleZafgen Announces Third Quarter 2015 Financial Results
Nov 3, 2015
Summary ToggleZafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results
BOSTON, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that it will host a conference call on Tuesday, November
Summary ToggleZafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results